Bird & Bird secures a win before the UK High Court for Gilead

Bird & Bird’s London patent team has secured a win before the UK High Court for their client Gilead, a global pharmaceutical company known for its work in the medical fields of virology, oncology and inflammation.

On 21 March 2023, Mr Justice Meade held that two patents owned by the Defendant NuCana were invalid for added matter, lack of plausibility and insufficiency including on the basis of the undue burden involved in making the class of “2-methyl up 2-fluorine down” compounds, such as sofosbuvir, falling within the claims. Sofosbuvir is the key component of Gilead’s new class of anti-viral drugs (Solvaldi, Harvoni, Vosevi and Epclusa) that act as inhibitors of an essential enzyme of the Hepatitis C virus. The compound has achieved blockbuster status, with the capability to effectively cure Hepatitis C on a global scale.

In this judgment, the Judge not only considered plausibility, but also “implausibility”, in view of the upcoming decision of the EPO Enlarged Board of Appeal (G2/21, Sumitomo), which has the potential to change the way patentability is assessed in all areas of technology, and particularly the Life Sciences industry.

Bird & Bird’s team comprised IP partners Patrick Kelleher, Jennifer Jones as well as associates Henry Elliott, Ning-Ning Li, Patrick Brown and Josh Price.

News & Deals

More News & Deals
Deal Bird & Bird advises ECBF on Series A financing round in Vegdog

Sep 16 2025

Read More
Deal Bird & Bird advises the University of Hong Kong on the acquisition of a building in Barcelona for its first educational project in Europe

Sep 16 2025

Read More
News Bird & Bird appoints Chris Case as partner in Australia

Sep 16 2025

Read More
Deal Bird & Bird advises Kingyue International and Evolve Capital on Mandatory Unconditional Cash Offer for Samko Timber

Sep 15 2025

Read More
News Bird & Bird appoints energy expert Jenny Murray as new partner

Sep 15 2025

Read More
News Bird & Bird strengthens disputes capability in Life Sciences with French partner appointment

Sep 15 2025

Read More